Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer (SN-FNAC)

Centre hospitalier de l'Université de Montréal (CHUM)

Status

Completed

Conditions

Breast Cancer

Invasive Breast Cancer

Treatments

Procedure: Sentinel Lymph Node Biopsy

Study type

Interventional

Funder types

Other

Identifiers

CE 08.224

Details and patient eligibility

About

Title of Study: Sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer.

Objectives of the study:

Primary objective

Evaluate the accuracy of sentinel node biopsy in breast cancer patients presenting with positive nodal disease, proven by ultrasound guided fine needle aspiration, following neoadjuvant chemotherapy.

Secondary objectives

Evaluate the technical success of sentinel node biopsy following neoadjuvant chemotherapy.
Evaluate the accuracy of clinical examination and ultrasound examination of the axilla in identifying the presence of residual disease in the axilla following neoadjuvant chemotherapy in biopsy proven node positive breast cancer patients.

Number of patients:

N = 300

Population:

Patients with unresected breast cancer that are eligible for neoadjuvant chemotherapy that present with biopsy proven positive axillary nodes.

Study duration:

From February 2009 to February 2012 - 3 years

Enrollment

153 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Conditions for patient eligibility

Inclusion criteria:

Patients must be female.
Patients must be 18 years of age or older.
Patients with stage IIA, IIB, IIIA (T1-3 and N1-2) breast cancer. Clinical N0 accepted if biopsy proven node disease.
Patients that have biopsy proven positive axillary disease made by core needle biopsy or fine needle aspiration .
Patients that accept to undergo neoadjuvant chemotherapy; patients are eligible until the day of surgery.
Patients with bilateral breast cancer are eligible. Sentinel node biopsy is allowed on the contralateral breast if there is no disease in the axilla prior to chemotherapy.
Patients that understand, accept and have signed the approved consent form.

Exclusion Criteria:

Patients with inflammatory breast cancer.
Patient with stage IIIB, IIIC or IV breast cancer (T4 and N3) Patients with clinical N3 disease are excluded.
Patients that have had previous axillary dissection or an axillary sentinel node biopsy; (patients that have had excisional biopsy or ipsilateral tumorectomy are eligible).
Patients that have had previous radiotherapy to the axillary nodes
Patients that have had mammary reduction
Patients that are medically unfit to receive chemotherapy, as evaluated by the treating physician.
If the injection of blue dye is planned, patients with hypersensitivity or allergy to isosulfan blue, Patent blue or methylene blue or radiocolloid dye are ineligible.
Patients who are pregnant or breast feeding .
Psychiatric or addictive disorders or other conditions that preclude the patient from meeting the study requirements.